Keywords: ساکساگلپتین; Gentamicin; Saxagliptin; Nephro-protection; TNFα; VCAM-1; Caspase-3;
مقالات ISI ساکساگلپتین (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: ساکساگلپتین; Chitosan; l-valine; Carbodiimide; Saxagliptin; Brain delivery; Rhodamine B;
Keywords: ساکساگلپتین; Saxagliptin; Pre-diabetes; Obesity; Islet function; Monotherapy; Metformin;
Keywords: ساکساگلپتین; dapagliflozin; dipeptidyl peptidase-4 (DPP-4) inhibitor; drug interaction; saxagliptin; sodium-glucose cotransporter 2 (SGLT-2) inhibitor;
Keywords: ساکساگلپتین; Saxagliptin; Kidney injury; Renal dipeptidyl peptidase-4; Dahl salt-sensitive hypertensive rat;
Keywords: ساکساگلپتین; Dipeptidyl peptidase-4; Saxagliptin; Parkinson disease; Dopamine; Rotenone; cAMP; BDNF; Apoptosis; Free radical; 6-OHD; 6-hydroxydopamine; AD; Alzheimer's disease; ADP; adenosine diphosphate; ATP; adenosine triphosphate; Bcl-2; B-cell lymphoma-2; BDNF; br
Keywords: ساکساگلپتین; Vildagliptin; Saxagliptin; Experimental design; Dansylation; Charge transfer reaction; Hantzsch reaction
Keywords: ساکساگلپتین; GV; glycaemic variability; HbA1c; glycosylated hemoglobin; T2DM; type 2 diabetes mellitus; FBG; fasting blood glucose; SMBG; self-monitoring of blood glucose; IDF; International Diabetes Federation; SDBG; standard deviation of blood glucose; LAGE; largest
Keywords: ساکساگلپتین; Bone microarchitecture; Diabetes mellitus; Saxagliptin; Dipeptidyl-peptidase 4; Osteoblasts; Bone marrow stromal cells
Ammonolysis of (5S)-N-(tert-butoxycarbonyl)-5-(methoxycarbonyl)-2-pyrroline with immobilized Candida antarctica lipase B (CAL B) in a packed bed reactor
Keywords: ساکساگلپتین; Biocatalysis; Immobilised enzymes; Fixed-bed bioreactors; Lipase; Kinetic parameters; Ammonolysis; Saxagliptin;
Worsening Heart Failure During the Use of DPP-4 Inhibitors
Keywords: ساکساگلپتین; diabetes; DPP-4 inhibitors; heart failure risk; saxagliptin; sitagliptin; AMP; adenosine monophosphate; DPP; dipeptidyl peptidase; GLP; glucagon-like peptide; SDF; stromal cell-derived factor; SGLT2; sodium-glucose transporter 2;
Antidiabetic “gliptins” affect biofilm formation by Streptococcus mutans
Keywords: ساکساگلپتین; Streptococcus mutans; Biofilm; X-prolyl dipeptidyl peptidase; Saxagliptin; Shot-gun proteomics;
The persistent inhibitory properties of saxagliptin on renal dipeptidyl peptidase-4: Studies with HK-2 cells in vitro and normal rats in vivo
Keywords: ساکساگلپتین; Dipeptidyl peptidase-4 inhibitor; Saxagliptin; Sitagliptin; Renal dipeptidyl peptidase-4; Renal tubular cells;
Short-term therapy with combination dipeptidyl peptidase-4 inhibitor saxagliptin/metformin extended release (XR) is superior to saxagliptin or metformin XR monotherapy in prediabetic women with polycystic ovary syndrome: a single-blind, randomized, pilot
Keywords: ساکساگلپتین; Dipeptidyl peptidase-4 inhibitor; polycystic ovary syndrome; prediabetic hyperglycemia; saxagliptin;
A post hoc analysis of saxagliptin efficacy and safety in patients with type 2 diabetes stratified by UKPDS 10-year cardiovascular risk score
Keywords: ساکساگلپتین; Coronary heart disease; Saxagliptin; Stroke; Type 2 diabetes; UKPDS risk scoreADA, American Diabetes Association; AEs, adverse events; CHD, coronary heart disease; CV, cardiovascular; CVD, cardiovascular disease; DPP-4, dipeptidyl peptidase-4; EASD, Europ
Cardiac DPP-4 inhibition by saxagliptin ameliorates isoproterenol-induced myocardial remodeling and cardiac diastolic dysfunction in rats
Keywords: ساکساگلپتین; Dipeptidyl peptidase-4 inhibitor; Saxagliptin; Myocardial remodeling; Cardiac diastolic dysfunction; Cardiac dipeptidyl peptidase-4;
Dipeptidyl peptidase-4 inhibitors and heart failure: Analysis of spontaneous reports submitted to the FDA Adverse Event Reporting System
Keywords: ساکساگلپتین; Dipeptidyl peptidase-4 inhibitors; Sitagliptin; Saxagliptin; Heart failure; Drug safety; Disproportionality; Spontaneous reporting system; FAERS
Pulmonary, gastrointestinal and urogenital pharmacologyGlucose-independent renoprotective mechanisms of the tissue dipeptidyl peptidase-4 inhibitor, saxagliptin, in Dahl salt-sensitive hypertensive rats
Keywords: ساکساگلپتین; Saxagliptin; Kidney injury; Renal dipeptidyl peptidase-4; Inflammation; Fibrosis;
Efficacy and safety of saxagliptin, a dipeptidyl peptidase-4 inhibitor, in hemodialysis patients with diabetic nephropathy: A randomized open-label prospective trial
Keywords: ساکساگلپتین; Saxagliptin; Hemodialysis; Type 2 diabetes; Glycated albumin;
Effects of Glimepiride versus Saxagliptin on β-Cell Function and Hypoglycemia: A Post Hoc Analysis in Older Patients with Type 2 Diabetes Inadequately Controlled with Metformin
Keywords: ساکساگلپتین; β-cell function; dipeptidyl peptidase-4 inhibitor; homeostasis model assessment-2%β; saxagliptin;
Ãtude de la saxagliptine sur la survenue d'événements cardiovasculaires chez des patients diabétiques de type 2 (Ãtude SAVOR-TIMI 53) : les résultats
Keywords: ساکساگلپتین; Incrétines; prévention cardiovasculaire; inhibiteurs de la DPP-4; saxagliptine; Incretins; cardiovascular outcomes; DPP-4 inhibitors; saxagliptin;
Saxagliptin improves glycemic control by modulating postprandial glucagon and C-peptide levels in Chinese patients with type 2 diabetes
Keywords: ساکساگلپتین; China; DPP-4 inhibitors; Mixed-meal tolerance test; Saxagliptin; Type 2 diabetes mellitus
Synthesis and biological evaluation of all eight stereoisomers of DPP-IV inhibitor saxagliptin
Keywords: ساکساگلپتین; Saxagliptin; Stereoisomers; Synthesis; Configuration–activity relationship; DPP-IV inhibitors
Influences of processed rhubarbs on the activities of four CYP isozymes and the metabolism of saxagliptin in rats based on probe cocktail and pharmacokinetics approaches
Keywords: ساکساگلپتین; Rheum palmatum; Cooked rhubarb; Wine processed rhubarb; CYP isozyme; Saxagliptin; Herb-drug interaction;
Ãtude de la saxagliptine sur la survenue d'événements cardiovasculaires chez des patients diabétiques de type 2 (étude SAVOR-TIMI 53) : description de l'étude et des patients
Keywords: ساکساگلپتین; Diabète de type 2; saxagliptine; prévention cardiovasculaire; stratégie thérapeutique; sécurité; Type 2 diabetes; saxagliptin; cardiovascular prevention; therapeutic strategy; drug safety;
Spectrophotometric and spectrofluorimetric methods for the determination of saxagliptin and vildagliptin in bulk and pharmaceutical preparations
Keywords: ساکساگلپتین; Saxagliptin; Vildagliptin; 1,2-Naphthoquinone-4-sulfonic acid sodium salt; 4-Chloro-7-nitrobenzofurazan; Spectrophotometry; Spectrofluorimetry
Cost-effectiveness of saxagliptin (Onglyza®) in type 2 diabetes in Sweden
Keywords: ساکساگلپتین; Cost-effectiveness; Utility; Economic modeling; HbA1c; Hypoglycaemia; Type 2 diabetes; Sulphonylurea; Saxagliptin; Diabetes-related complications
Liquid chromatography and tandem mass spectrometry method for the quantitative determination of saxagliptin and its major pharmacologically active 5-monohydroxy metabolite in human plasma: Method validation and overcoming specific and non-specific binding
Keywords: ساکساگلپتین; Antidiabetic agent; Onglyzaâ¢; Saxagliptin; BMS-477118; 5-Hydroxy saxagliptin metabolite; Dipeptide-peptidase; DPP4; LC-MS/MS; Liquid chromatography-tandem mass spectrometry; Diastereomer; Protein precipitation; Human plasma; Cross-validation;
DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trials
Keywords: ساکساگلپتین; Clinical trial-DPP-4 inhibitor; Alogliptin; Linagliptin; Saxagliptin; Sitagliptin; Vildagliptin; Type 2 diabetes mellitus; ReviewDiabète de type 2; Essai clinique; Inhibiteur de la DPP-4; Alogliptine; Linagliptine; Saxagliptine; Sitagliptine; Vildagliptin
GLP-1 for type 2 diabetes
Keywords: ساکساگلپتین; GLP-1; DPP-4 inhibition; Type 2 diabetes; Exenatide; Liraglutide; Albiglutide; Taspoglutide; Lixisenatide; Sitagliptin; Vildagliptin; Saxagliptin; Alogliptin; Linagliptin
Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: A randomized controlled trial
Keywords: ساکساگلپتین; DPP-4 inhibitor; Incretins; Glycemic control; Metformin; Saxagliptin
Saxagliptin: A Clinical Review in the Treatment of Type 2 Diabetes Mellitus
Keywords: ساکساگلپتین; dipeptidyl peptidase-4 inhibitors; glucagon-like peptide 1; saxagliptin; type 2 diabetes
Tolerability of Dipeptidyl Peptidase-4 Inhibitors: A Review
Keywords: ساکساگلپتین; alogliptin; dipeptidyl peptidase-4 (DPP-4) inhibitor; linagliptin; saxagliptin; sitagliptin; vildagliptin
Clinical Pharmacology of Incretin Therapies for Type 2 Diabetes Mellitus: Implications for Treatment
Keywords: ساکساگلپتین; alogliptin; DPP-4 inhibitors; exenatide; GLP-1 receptor agonists; incretin therapies; liraglutide; saxagliptin; sitagliptin; type 2 diabetes; vildagliptin;
Treatment of elderly patients with type 2 diabetes mellitus: A systematic review of the benefits and risks of dipeptidyl peptidase-4 inhibitors
Keywords: ساکساگلپتین; alogliptin; cardiovascular; hypoglycemia; obesity; saxagliptin; sitagliptin; vildagliptin;
Mechanism of Gly-Pro-pNA cleavage catalyzed by dipeptidyl peptidase-IV and its inhibition by saxagliptin (BMS-477118)
Keywords: ساکساگلپتین; Serine protease; Human DPP-IV; Diabetes; GLP-1; Mechanism of inhibition; Dipeptide cleavage; Saxagliptin; Covalent intermediate